Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1

Arthritis and Rheumatology

Volumn 68, Issue 2, 2016, Pages 473-483

  Lemaire, Raphaël ^a,b   Burwell, Timothy ^a   Sun, Hong ^a   Delaney, Tracy ^a   Bakken, Julie ^a   Cheng, Lily ^a   Rebelatto, Marlon C ^a   Czapiga, Meggan ^a   De Mendez, Isabelle ^a   Coyle, Anthony J ^a   Herbst, Ronald ^a   Lafyatis, Robert ^b   Connor, Jane ^a  

^a MEDIMMUNE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD4 ANTIGEN; COLLAGEN; INTERLEUKIN 33; INTERLEUKIN 4 RECEPTOR ALPHA; INTERSTITIAL COLLAGENASE; KALLIKREIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PAI 1; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UROKINASE; VASCULAR CELL ADHESION MOLECULE 1; ANTINEOPLASTIC ANTIBIOTIC; MMP1 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; DERMATITIS; ENDOTHELIUM; ENZYME ACTIVATION; EPIDERMIS; FIBRINOLYSIS; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; ANIMAL; CASE CONTROL STUDY; CHEMICALLY INDUCED; DIFFUSE SCLERODERMA; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; FIBROSIS; LIMITED SCLERODERMA; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SKIN;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BLEOMYCIN; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBROSIS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 1; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SKIN;

EID: 84956711613     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39443     Document Type: Article

References (33)

1. Korn J., Pathogenesis of systemic sclerosis (scleroderma). In:, Koopman WJ, editor. Arthritis and allied Conditions: a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1643-54.
2. Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L, et al., The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 1997; 36: 1045-50.
3. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D., Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83: 351-6.
4. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D., Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-33.
5. Erickson LA, Ginsberg MH, Loskutoff DJ., Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
6. Robbie LA, Booth NA, Brown AJ, Bennett B., Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539-45.
7. Robbie LA, Young SP, Bennett B, Booth NA., Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and RAI-1 content and distribution. Thromb Haemost 1997; 77: 510-5.
8. Cesari M, Pahor M, Incalzi RA., Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28: e72-91.
9. Schar CR, Jensen JK, Christensen A, Blouse GE, Andreasen PA, Peterson CB., Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 2008; 283: 28487-96.
10. De Waard V, Arkenbout EK, Carmeliet P, Lindner V, Pannekoek H., Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol 2002; 22: 1978-83.
11. Wu J, Peng L, McMahon GA, Lawrence DA, Fay WP., Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia. Arterioscler Thromb Vasc Biol 2009; 29: 1565-70.
12. Alexander CM, Werb Z., Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989; 1: 974-82.
13. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, et al., Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 1989; 86: 2632-6.
14. Vousden KA, Popovic B, Lundqvist T, Naiman B, Carruthers AM, Newton P, et al., Molecular basis for the potent inhibition of plasminogen activator inhibitor-1 by a monoclonal antibody. Submitted for publication.
15. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
16. Farina G, Lafyatis D, Lemaire R, Lafyatis R., A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-8.
17. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD., A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004; 50: 1319-31.
18. Swiatkowska M, Szemraj J, Cierniewski CS., Induction of PAI-1 expression by tumor necrosis factor α in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J 2005; 272: 5821-31.
19. Bugge TH, Flick MJ, Daugherty CC, Degen JL., Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.
20. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, et al., Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-93.
21. Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Collen D, et al., Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81: 601-4.
22. Schafer K, Konstantinides S, Riedel C, Thinnes T, Muller K, Dellas C, et al., Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation 2002; 106: 1847-52.
23. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP., Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97: 1002-8.
24. Kawasaki T, Dewerchin M, Lijnen HR, Vermylen J, Hoylaerts MF., Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 2000; 96: 153-60.
25. Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, et al., Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107: 132-4.
26. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D., Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99: 200-8.
27. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP., Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol 2002; 22: 934-9.
28. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA, Castellino FJ., Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol 2001; 158: 107-17.
29. Otsuka G, Agah R, Frutkin AD, Wight TN, Dichek DA., Transforming growth factor β1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 2006; 26: 737-43.
30. Lijnen HR, Van Hoef B, Umans K, Collen D., Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost 2004; 2: 16-22.
31. Alvarez D, Harder G, Fattouh R, Sun J, Goncharova S, Stampfli MR, et al., Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses. J Immunol 2005; 174: 1664-74.
32. Aden N, Shiwen X, Aden D, Black C, Nuttall A, Denton CP, et al., Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 2008; 47: 1754-60.
33. Wang L, Ly CM, Ko CY, Meyers EE, Lawrence DA, Bernstein AM., uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin. Invest Ophthalmol Vis Sci 2012; 53: 4765-75.